IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene FOLR1 Ensembl ENSG00000110195 Chromosome 11 Start 71578250 End 71584990
Description Folate receptor alpha Precursor (FR-alpha)(Folate receptor 1)(Folate receptor, adult)(Adult folate-binding protein)(FBP)(Ovarian tumor-associated antigen MOv18)(KB cells FBP) [Source:UniProtKB/Swiss-Prot;Acc:P15328]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 3791
     Entrez Gene : 2348
     UCSC : uc001osa.1
     GeneCards : 3791
     RefSeq : NM_000802
     CCDS : CCDS8211.1
     Uniprot : P15328
     Interpro : P15328
     OMIM : 136430
     GeneTests : FOLR1
     CGAP : FOLR1
     PMID : 1717147

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
down - RT-PCT- 18394749 Lung Cancer. 2008 Oct;62(1):23-34.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  39311_at  -1.85  2.92e-8  2.67e-7  -4.10  1.10e-32  4.61e-29
 HG_U95  534_s_at  -0.70  1.86e-7  1.44e-6  -1.37  8.31e-21  1.02e-18
 HG_U95  821_s_at  -1.71  2.80e-7  2.08e-6  -4.19  3.43e-24  1.08e-21
 HG_U133A  204437_s_at  -1.34  6.04e-12  2.55e-11  -3.32  5.13e-109  4.46e-108
 HG_U133A  211074_at  -0.12  4.18e-1  4.74e-1  -6.19  1.87e-101  1.32e-100
 HG_U133_Plus2  204437_s_at  -1.69  1.40e-10  1.10e-9  -3.85  2.98e-38  4.20e-36
 HG_U133_Plus2  211074_at  0.63  4.35e-5  1.48e-4  0.45  5.79e-3  9.84e-3
 Stanford  9108  -1.93  8.76e-3  5.91e-2  -4.61  4.18e-11  3.37e-7
 Agilent_HS_21.6K  15974  -0.30  5.37e-2  1.53e-1  -0.74  6.33e-9  2.03e-7

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204437_s_at  -0.05  9.29e-1  9.95e-1  -0.10  7.32e-1  1.00e+0
 HG_U133A  211074_at  0.10  8.54e-1  9.88e-1  -0.07  6.80e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 39311_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 534_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 821_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204437_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211074_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204437_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211074_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 9108    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 15974    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
mov18 ovarian cancer Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. 12242512 Human
fbp breast cancers The folate binding protein (FBP) is overexpressed in over 90% of ovarian and 20-50% in breast cancers. 12497651 Human
fbp breast cancer The FBP is the source of the antigenic peptides that are recognized by a number of these CTL-TAL, and is antigenic to both ovarian and breast cancer in vivo. 12497651 Human
mov18 colorectal carcinomas Monoclonal antibodies C215, reactive with colorectal carcinomas, and MOv18, reactive with most of the ovarian carcinomas, were radiohalogenated with [211At]astatine. 11182562 Human
mov18 ovarian carcinomas Monoclonal antibodies C215, reactive with colorectal carcinomas, and MOv18, reactive with most of the ovarian carcinomas, were radiohalogenated with [211At]astatine. 11182562 Human
mov18 ovarian cancer Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. 11279613 Human
mov18 ovarian carcinoma MOv18 antibody binds the membrane folate receptor highly expressed on ovarian carcinoma cells. 11279613 Human
mov18 human ovarian cancer Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. 11299770 Human
mov18 ovarian cancer Immunoscintigraphy of ovarian cancer lesions has been performed mainly with 99mTc, 111In and 123I labeled with HMFG1, HMFG2, OC-125, B72.3, H17E2, OVTL3, MoAb170, Mov18 and other MoAbs. 11669325 Human
mov18 ovarian cancer Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. 10769696 Human
mov18 tumour When the mice were treated with 211At-labelled MOv18 intraperitoneally 9 out of 10 were apparently free of both ascites and tumour compared to none of the mice given unlabelled antibody. 10769696 Mouse
mov18 ovarian cancer Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. 10914906 Human
mov18 tumor We investigated the safety and pharmacokinetics of (131)I-labeled chimeric monoclonal antibody MOv18 ((131)I-c-MOv18 IgG) in patients with ovarian cancer and the estimated radiation dose to cancer-free organs and tumor. 10914906 Human
mov18 ovarian cancer We investigated the safety and pharmacokinetics of (131)I-labeled chimeric monoclonal antibody MOv18 ((131)I-c-MOv18 IgG) in patients with ovarian cancer and the estimated radiation dose to cancer-free organs and tumor. 10914906 Human
mov18 ovarian cancer The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study. 11130014 Human
mov18 human ovarian cancer The purpose of the present study was to investigate the therapeutic efficacy of 211At-labelled specific monoclonal antibody MOv18 in nude mice with intraperitoneal growth of the human ovarian cancer cell line OVCAR3. 11130014 Human
fbp breast cancer In this study, we demonstrate that the human high-affinity folate binding protein (FBP), which is a source of antigenic peptides recognized in ovarian cancer, is also recognized in breast cancer. 10632363 Human
fbp ovarian cancer In this study, we demonstrate that the human high-affinity folate binding protein (FBP), which is a source of antigenic peptides recognized in ovarian cancer, is also recognized in breast cancer. 10632363 Human
fbp cancers Both immunodominant E39 (FBP, 191-199) and subdominant E41 (FBP, 245-253) epitopes are presented by HLA-A2 in these cancers. 10632363 Human
fbp endometrial carcinomas The broad distribution of FBP among >90% of ovarian and endometrial carcinomas, as well as 20-50% of breast, lung, colorectal, and renal cell carcinomas, along with pronounced differential overexpression in malignant tissues compared with the extremely li 10632363 Human
fbp renal-cell carcinomas The broad distribution of FBP among >90% of ovarian and endometrial carcinomas, as well as 20-50% of breast, lung, colorectal, and renal cell carcinomas, along with pronounced differential overexpression in malignant tissues compared with the extremely li 10632363 Human
fbp epithelial cancers The broad distribution of FBP among >90% of ovarian and endometrial carcinomas, as well as 20-50% of breast, lung, colorectal, and renal cell carcinomas, along with pronounced differential overexpression in malignant tissues compared with the extremely li 10632363 Human
fbp breast cancers The folate binding protein (FBP) is overexpressed in over 90% of ovarian and 20-50% of breast cancers. 10652572 Human
fbp inflammatory bowel disease Antibodies to folate-binding protein (FBP) of cow's milk were studied in serum from patients with chronic inflammatory bowel disease (CIBD), since earlier studies had shown IgG- and IgM-serum antibodies to other isotypes of milk proteins to be elevat 2636225 Human
mov18 human ovarian carcinoma In the perspective of therapeutic in vivo targeting for T-cell attack, the monoclonal antibody (MAb) MOv18, selected for its restricted reactivity with human ovarian carcinoma, and an anti-T3 MAb were used to produce heteroconjugate or hybrid antibodies d 3258291 Human
mov18 human ovarian carcinoma In the perspective of in vivo therapeutic applications, the monoclonal antibody (MAb) MOv18 was selected for its restricted reactivity with human ovarian carcinoma. 3258590 Human
mov18 ovarian carcinoma The maintenance of the binding reactivity and specificity of the bispecific MAbs was analyzed by solid-phase radioimmunoassay, immunofluorescence and cross-competition tests on the relevant target cells (ovarian carcinoma cell line OVCA 432 for MOv18 and 3258590 Human
mov18 tumor The maintenance of the binding reactivity and specificity of the bispecific MAbs was analyzed by solid-phase radioimmunoassay, immunofluorescence and cross-competition tests on the relevant target cells (ovarian carcinoma cell line OVCA 432 for MOv18 and 3258590 Human
mov18 ovarian carcinomas In contrast, MOv18 and MOv19 appeared to have restricted specificities for ovarian carcinomas and cystadenomas. 2434438 Human
mov18 tumors At-211 MOv18 was found to effectively inhibit the development of tumors and ascites, also resulting in long-term survival without significant toxic effect. 14506189 Mouse
mov 18 ovarian cancer Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. 10380823 Human
mov18 tumours The biodistribution of the radiolabelled monoclonal antibodies MOv18, OV185 and OV197 in nude mice with subcutaneous tumours of the human ovarian cancer cell line OVCAR3 was investigated. 10380823 Human
mov18 human ovarian cancer The biodistribution of the radiolabelled monoclonal antibodies MOv18, OV185 and OV197 in nude mice with subcutaneous tumours of the human ovarian cancer cell line OVCAR3 was investigated. 10380823 Human
mov18 tumour The early uptake of MOv18 (1-24 h) and the uptake in relation to tumour size were also studied. 10380823 Mouse
mov 18 tumour The tumour/blood ratio and the localization index for Mov 18 72 h after antibody injection were 2.21 +/- 0.25 and 4.62 +/- 1.27, respectively. 10380823 Human
mov18 tumour The early tumour uptake of MOv18 was low with a tumour/blood ratio of 0.23 +/- 0.04 after 6 h, and the uptake was higher in small tumours. 10380823 Human
mov18 tumours The early tumour uptake of MOv18 was low with a tumour/blood ratio of 0.23 +/- 0.04 after 6 h, and the uptake was higher in small tumours. 10380823 Human
fbp tumor A longitudinal study will determine if these changes in FBP concentrations precede tumor onset. 10390055 Human
fralpha ovarian carcinoma Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes. 10419053 Human
fralpha metastases Vaccination with the FRalpha and interleukin-2 cDNA mixture, which was performed after an intravenous injection of FRalpha-transduced cells, enhanced the mean survival time and reduced the number of lung metastases, thus suggesting that such vaccination i 10419053 Human
fralpha tumor Vaccination with the FRalpha and interleukin-2 cDNA mixture, which was performed after an intravenous injection of FRalpha-transduced cells, enhanced the mean survival time and reduced the number of lung metastases, thus suggesting that such vaccination i 10419053 Human
fbp human ovarian carcinoma To test this hypothesis, we developed an in vitro model based on primary human ovarian carcinoma (OC) cultures and BsAbs directed against human T cells and several tumor markers [placental alkaline phosphatase (PLAP), GCAP, folate-binding protein (FBP) an 10471538 Human
fbp tumor To test this hypothesis, we developed an in vitro model based on primary human ovarian carcinoma (OC) cultures and BsAbs directed against human T cells and several tumor markers [placental alkaline phosphatase (PLAP), GCAP, folate-binding protein (FBP) an 10471538 Human
fr-alpha tumors In the ovary, benign differentiation of the germinal epithelium into mucinous or serous tumors or malignant transformation into mucinous tumors is associated with down-regulation of FR-alpha, whereas FR-alpha expression is retained in malignant lesions of 10498396 Human
fr alpha colon adenocarcinoma The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor alpha (FR alpha) as an additional antigen in order to study the efficacy of vac 10505112 Human
fr alpha tumor The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor alpha (FR alpha) as an additional antigen in order to study the efficacy of vac 10505112 Human
fr alpha metastases A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12/FR alpha that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FR alpha. 10505112 Human
fr alpha tumor However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26-related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FR alpha antigen. 10505112 Human
fr alpha tumors Tumors obtained from mice that died despite vaccination lost expression of the FR alpha transgene but maintained expression of endogenous C26 antigens. 10505112 Mouse
fr alpha tumors Immunoselection against FR alpha antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. 10505112 Mouse
fr-alpha human ovarian carcinomas Folate receptor-alpha (FR-alpha) is generally over-expressed in non-mucinous human ovarian carcinomas. 9426700 Human
fr-alpha tumors The meaning of FR-alpha over-expression and its role in the 5-methyltetrahydrofolic acid (N5-CH3-H4PteGlu) transport in such tumors is not clear, especially compared with the reduced folate carrier (RFC), the other known folate transporter. 9426700 Human
fr-alpha ovarian carcinoma In this study, we analyzed molecular FR-alpha and RFC expression in 16 ovarian carcinoma tissues and in 5 ovarian carcinoma cell lines using competitive PCR. 9426700 Human
fr-alpha ovarian carcinoma The 5 ovarian carcinoma cell lines (IGROV-1, SW-626, SKOV-3, OVCAR-3 and OAW-42), grown at physiological N5-CH3-H4PteGlu concentrations (20 nM) and expressing FR-alpha and RFC levels superimposable to those observed in vivo, were used as in vitro cellular 9426700 Human
fr-alpha ovarian carcinomas Our findings suggest that in ovarian carcinomas, in spite of its over-expression, FR-alpha generally plays a minor role in N5-CH3-H4PteGlu transport compared with RFC. 9426700 Human
fbp human ovarian carcinomas Using the technique of "guided selection," we generated human Ab against the high-affinity folate-binding protein (FBP), a cell surface Ag that is overexpressed in many human ovarian carcinomas. 9500461 Human
fbp ovarian carcinoma The guiding Ab template was provided by the light chain of mouse monoclonal Ab Mov19 (K[aff], 10[8] M[-1]) directed against FBP; this was paired with repertoires of human heavy chains displayed on phages, and the hybrid Ab fragments were selected by bindi 9500461 Human
fbp ovarian carcinoma This was highly specific for FBP, as demonstrated by ELISA and flow cytometry data and by immunoprecipitation of the relevant molecule from the cell surface of ovarian carcinoma cells. 9500461 Human
fbp epithelial ovarian cancer Overexpression of the folate binding protein (FBP) is a common feature in epithelial ovarian cancer, but its prognostic significance is not clearly understood. 9583724 Human
fbp epithelial ovarian cancer We investigated whether FBP in epithelial ovarian cancer specimens is a predictor of response to chemotherapy and survival. 9583724 Human
fbp tumors In the 58 patients with residual disease after primary surgery, failure to respond to chemotherapy (complete or partial remission) was about 15-fold higher (95% confidence interval, 2.96-77.43) when tumors had FBP FI above the median value (FBP FI = 3.25) 9583724 Human
fbp tumors FBP FI was not a predictor of survival in the entire series of tumors (99 patients). 9583724 Human
fbp ovarian cancer In conclusion, higher levels of FBP expression might be a predictor of chemotherapy response failure in ovarian cancer. 9583724 Human
fr alpha tumor In addition to identifying the machinery for receptor-mediated folate uptake, it may be important to integrate this new data into studies of FR alpha as a tumor antigen for imaging or delivering molecules via anti-FR antibodies or compounds coupled to fol 9679952 Human
fbp ovarian carcinoma Tumor tissue specimens from five patients with ovarian carcinoma contained immunoreactive FBP. 9743473 Human
fbp tumor Tumor tissue specimens from five patients with ovarian carcinoma contained immunoreactive FBP. 9743473 Human
fbp ovarian cancers Therefore, we have investigated peptides derived from folate binding protein (FBP), which is over-expressed in more than 90% of ovarian cancers and in the majority of other epithelial tumors. 9869522 Human
fbp ovarian cancer CONCLUSIONS: FBP peptides are recognized by freshly isolated TAL from ovarian cancer patients, suggesting in vivo expression and sensitization. 9869522 Human
fbp myelodysplastic syndromes OBJECTIVE: To observe the characteristics of folate binding proteins (FBP) in myelodysplastic syndromes (MDS) and leukemia and to study the clinical significance of reduced folate carrier (RFC) present in MDS and its relationship with multidrug resistance 10374424 Human
fbp ovarian carcinoma The overexpression of FBP on the cell surface of ovarian carcinoma cells may be responsible for an increased folate uptake. 9099956 Human
fbp ovarian cancers The high affinity folate binding protein (FBP) is overexpressed in ovarian cancers. 9133455 Human
fbp epithelial ovarian cancer Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer. 9133455 Human
mov 18 epithelial ovarian cancer Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer. 9133455 Human
fbp tumours Some amount of FBP overexpression was observed in 122 of the 136 tumours examined. 9133455 Human
fbp ovarian neoplasms By univariate analysis, FBP FI was overexpressed to a higher degree in ovarian neoplasms with high histologic grade, advanced stage, serous histology, aneuploid status, and high percentage of cells in S-phase. 9133455 Human
fbp ovarian cancers Our results indicate that FBP is associated with parameters of biological aggressiveness in ovarian cancers. 9133455 Human
mov18 malignant ovarian tumors The ovarian tumor markers (OC125, OV-TL 33, OV-TL16, MOv18), all showed an increasing expression level in the sequence order from normal cells to benign and malignant ovarian tumors. 9167042 Human
fr alpha ovarian carcinoma We investigated whether the folate receptor alpha-isoform (FR alpha), which is overexpressed on ovarian carcinoma cells, is functionally active in internalizing the physiological form et folate, 5-methyl tetrahydrofolate (THF). 9178098 Human
fr alpha tumor These findings suggest that the internalization of 5-methylTHF in these tumor cells depends not only on the level of overexpressed FR alpha, but another transport route, with features characteristic for RFC, is functional and participates in folate uptake 9178098 Human
fbp ovarian carcinoma The results obtained on a panel of ten ovarian carcinoma cell lines that overexpress different levels of the FBP showed a statistically significant relationship between FBP overexpression and cisplatin responsiveness, with the most sensitive cell lines ex 9218736 Human
fbp ovarian carcinoma Analysis of two cisplatin-resistant cell lines derived from the cisplatin-sensitive IGROV1 ovarian carcinoma cell line indicated that resistance was associated with a significant decrease in FBP expression. 9218736 Human
fbp ovarian carcinoma Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity. 9218736 Human
mov18 ovarian cancer The anti-folate receptor (FR) MAb MOv18 has proven suitable for radioimmunodetection of ovarian cancer using directly radiolabeled MAb or in a two-step method. 9293791 Human
mov18 ovarian carcinoma In this study, we analyzed the suitability of MOv18 in a three-step protocol in ovarian carcinoma patients and the internalization events after formation of the MOv18-avidin complex. 9293791 Human
fbp ovarian carcinoma On this basis, we hypothesised that the overexpression of FBP in ovarian carcinoma might be physiologically associated with folate deficiency in the extracellular fluids, where ovarian carcinoma cells develop in vivo, or it might be the result of a reduce 9301457 Human
mov18 tumor Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. 9409456 Human
fbp ovarian carcinomas The bispecific OC/TR monoclonal antibody (mAb) cross-links the CD3 molecule on T cells with the human folate-binding protein (FBP), which is highly expressed on nonmucinous ovarian carcinomas. 9409456 Human
fbp myeloma Sp2/0 myeloma cells were transfected with chimeric heavy- and light-chain genes encoding the anti-CD3 mAb and the MOv18 mAb, respectively, which are reactive with FBP. 9409456 Human
fbp ovarian carcinoma Subsequently, we analysed four ovarian carcinoma cell lines (OVCAR3, IGROV1, SKOV3, and SW626) expressing different amounts of FBP. 8595169 Human
fbp cancer Although FBP expression is certainly one of the parameters affecting drug toxicity, taken alone it is not a sufficiently reliable predictor of cancer cell sensitivity to DDATHF. 8595169 Human
fbp ovarian carcinomas The enhanced expression of FBP in ovarian carcinomas provided a rational basis for clinical studies with specific monoclonal antibodies and some newly synthesized antifolate drugs. 8691264 Human
fbp tumor The autoradiographic findings were confirmed by testing sections from mixtures of antigen-positive and antigen-negative cells, by immunoperoxidase staining with MOv18 on tumor sections and by biochemical identification of FBP in membrane fractions from ti 8691264 Human
mov18 tumor The autoradiographic findings were confirmed by testing sections from mixtures of antigen-positive and antigen-negative cells, by immunoperoxidase staining with MOv18 on tumor sections and by biochemical identification of FBP in membrane fractions from ti 8691264 Human
fbp cancer Folate-binding protein (FBP) was identified and characterized in a pig liver cDNA library by screening with a 0.6 kb fragment from the cDNA of FBP from a human KB cell cancer line. 8920973 Human
fbp ovarian carcinomas The bi-mAb OC/TR, which recognizes the folate-binding protein (FBP) overexpressed in 90% of ovarian carcinomas and the CD3 molecule on T cells, has demonstrated efficacy in a clinical setting. 8968099 Human
mov18 ovarian carcinoma T lymphocytes of 8 patients with ovarian cancer were targeted to the tumor cells using F(ab')2 fragments of a bispecific monoclonal antibody (bsAb), specific for CD3 (a component of the T lymphocyte receptor for antigen) and for the folate receptor M 7829257 Human
mov18 tumor T lymphocytes of 8 patients with ovarian cancer were targeted to the tumor cells using F(ab')2 fragments of a bispecific monoclonal antibody (bsAb), specific for CD3 (a component of the T lymphocyte receptor for antigen) and for the folate receptor M 7829257 Human
mov18 ovarian cancer T lymphocytes of 8 patients with ovarian cancer were targeted to the tumor cells using F(ab')2 fragments of a bispecific monoclonal antibody (bsAb), specific for CD3 (a component of the T lymphocyte receptor for antigen) and for the folate receptor M 7829257 Human
mov18 ovarian adenocarcinomas In this study, we have examined the in vivo activity of murine T cells transduced with a chimeric receptor gene (MOv-gamma) derived from the mAb MOv18, which binds to a folate-binding protein overexpressed on most human ovarian adenocarcinomas. 7614473 Human
mov18 cancer Autoradiography showed that antibodies preferentially localized in areas with cancer cells, which were immunohistochemically positive for MOv18. 7615359 Human
mov18 ovarian cancer Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. 7640039 Human
mov18 ovarian cancer Sixteen of 19 enrolled patients with minimal residual disease of ovarian cancer (macroscopic disease < 5 mm or positive blind biopsies and/or positive peritoneal washing), demonstrated by surgical second-look, underwent intraperitoneal radioimmunotherapy 7640039 Human
mov18 ovarian carcinoma AIMS--To analyse the distribution of OV-TL 3 and MOv18 in normal ovarian tissue to determine which antibody is most suitable for (radio)immunotherapy of ovarian carcinoma. 7560169 Human
mov18 epithelial ovarian cancers OV-TL 3 and MOv18 reacted with 100% and 98% (45/46) of the 46 tested epithelial ovarian cancers, respectively. 7560169 Human
mov18 ovarian carcinoma In ovarian carcinoma tissue homogeneous staining of epithelial cells was observed with OV-TL 3 and more heterogeneous staining with MOv18. 7560169 Human
mov18 tumour In 12 and nine patients, respectively, a difference in staining intensity for OV-TL 3 and MOv18 was observed between various tumour samples from the same patient. 7560169 Human
fbp primary breast cancers Folate binding protein (FBP) and estrogen receptor (ER) content were determined in primary breast cancers of 48 patients. 4064054 Human
fbp tumor The mean FBP level was significantly higher in ER-negative tumors than in ER-positive tumors and largely independent of the degree of tumor involvement or menopausal status. 4064054 Human
fbp tumors The mean FBP level was significantly higher in ER-negative tumors than in ER-positive tumors and largely independent of the degree of tumor involvement or menopausal status. 4064054 Human
fbp tumors FBP correlated negatively with ER and this was most marked for tumors from postmenopausal women. 4064054 Human
mov18 ovarian carcinoma Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. 2383475 Human
mov18 carcinoma Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. 2383475 Human
mov18 human ovarian carcinomas The structure of the 38 kD cell surface glycoprotein identified by the monoclonal antibody MOv18 and specifically expressed by human ovarian carcinomas has been investigated at a molecular level. 2222426 Human
mov18 carcinomas This derivatized toxin was then coupled to monoclonal antibodies (MBr1, MLuC1, MLuC2, MOv17, MOv18, MOv19) which exhibited a restricted spectrum of reactivity against human carcinomas. 2783572 Human
mov 18 ovarian carcinoma The ovarian carcinoma markers (OV-TL 3, OV-TL 10, OC 125, MOV 18) were strongly positive on ovarian carcinomas and negative on colon carcinomas (or limited to traces of immunofluorescence on some samples). 2659540 Human
mov 18 ovarian carcinomas The ovarian carcinoma markers (OV-TL 3, OV-TL 10, OC 125, MOV 18) were strongly positive on ovarian carcinomas and negative on colon carcinomas (or limited to traces of immunofluorescence on some samples). 2659540 Human
mov 18 colon carcinomas The ovarian carcinoma markers (OV-TL 3, OV-TL 10, OC 125, MOV 18) were strongly positive on ovarian carcinomas and negative on colon carcinomas (or limited to traces of immunofluorescence on some samples). 2659540 Human
fbp nasopharyngeal carcinoma In this study, human FBP cDNA clones were isolated from human malignant nasopharyngeal carcinoma (KB) cell and placental cDNA libraries by means of oligonucleotide probes derived from determined internal amino acid sequences. 2768245 Human
fr-alpha tumor The folate receptor type alpha (FR-alpha) is a promising tumor marker and target. 12612090 Human
fr-alpha tumor Here, we investigate the mechanistic basis for the tumor specificity and vast overexpression of FR-alpha. 12612090 Human
fr-alpha acute-lymphocytic leukemia (all) Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
fbp epidermoid carcinoma Folate-binding protein (FBP) is responsible for the cellular transport of folate and methotrexate (MTX) in human KB (nasopharyngeal epidermoid carcinoma) cells. 7511899 Human
mov18 epithelial ovarian tumors The MOv18 (gamma 1, kappa) and MOv19 (gamma 2a, kappa) murine monoclonal antibodies (MAbs) recognize different epitopes on the human folate binding receptor which is overexpressed on 90% of nonmucinous epithelial ovarian tumors. 7512887 Human
mov18 ovarian cancer Using human peripheral blood mononuclear cells as effector cells and conditions that provide for maximum lysis (effector target = 50:1, saturating antibody concentration), the murine MOv18 MAb (IgG1) mediated variable levels of specific cytolysis of the t 7512887 Human
fr-alpha squamous-cell carcinomas FR-alpha alone was expressed in normal epithelial cells and was frequently strikingly elevated in a variety of carcinomas, with the exception of squamous cell carcinomas of the head and neck. 7513252 Human
fr-alpha carcinomas FR-alpha alone was expressed in normal epithelial cells and was frequently strikingly elevated in a variety of carcinomas, with the exception of squamous cell carcinomas of the head and neck. 7513252 Human
fr-alpha tumor Established tumor cell lines expressed FR-alpha virtually alone and did not reflect FR expression patterns in vivo. 7513252 Human
fr-alpha carcinomas CONCLUSIONS. Although FR-beta is the more common isoform, FR-alpha and FR-beta are differentially regulated in normal tissues, carcinomas, nonepithelial malignancies, and immortalized cells or in response to changes in extracellular folate concentrations. 7513252 Human
mov 18 ovarian cancer For this purpose, we studied the effect of 5 cytokines (IFN-alpha, IFN-beta, IFN-gamma, TNF-alpha and TGF-beta), used as single agents or in combination, on 4 ovarian cancer cell lines which present different antigenic profiles with the monoclonal antibod 8169001 Human
mov18 ovarian carcinoma Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. 8204360 Human
fbp ovarian carcinomas Folate-binding proteins (FBP), which are molecules relevant in folate metabolism, are overexpressed in ovarian carcinomas, as detected by the monoclonal antibodies (MAb) MOv18 and MOv19, which recognise two different epitopes of the gp38/FBP. 8204360 Human
mov18 ovarian carcinomas Folate-binding proteins (FBP), which are molecules relevant in folate metabolism, are overexpressed in ovarian carcinomas, as detected by the monoclonal antibodies (MAb) MOv18 and MOv19, which recognise two different epitopes of the gp38/FBP. 8204360 Human
fbp tumour In this paper, features of the FBP such as the distribution on normal tissues and the release in biological fluids of normal and tumour origin have been investigated. 8204360 Human
fbp carcinomatosis By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. 8204360 Human
mov18 carcinomatosis By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. 8204360 Human
fbp carcinoma By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. 8204360 Human
mov18 carcinoma By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. 8204360 Human
fbp ovarian carcinoma In human biological fluids, the gp38/FBP was detected in ascites of 60% of ovarian carcinoma patients, and in 29% of those with other carcinomas, but not in patients with non-epithelial tumours or with other non-tumoral pathologies. 8204360 Human
fbp other carcinomas In human biological fluids, the gp38/FBP was detected in ascites of 60% of ovarian carcinoma patients, and in 29% of those with other carcinomas, but not in patients with non-epithelial tumours or with other non-tumoral pathologies. 8204360 Human
fbp tumours In human biological fluids, the gp38/FBP was detected in ascites of 60% of ovarian carcinoma patients, and in 29% of those with other carcinomas, but not in patients with non-epithelial tumours or with other non-tumoral pathologies. 8204360 Human
mov18 ovarian cancer Multiparameter flow cytometry using two different ovarian tumour markers (MOv18 and BMA180), an anti-cytokeratin monoclonal antibody (MAb) (M9), an anti-vimentin MAb (V9) and a MAb against the panepithelial antigen 17-1A on the fresh ascites cells of the 8054273 Human
fr-alpha choriocarcinoma Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in the human placental syncytiotrophoblast and choriocarcinoma cells. 8061055 Human
fr-alpha choriocarcinoma Reverse transcription coupled with polymerase chain reaction (RT-PCR) of total/poly(A)+ RNA from placenta, cultured trophoblast cells and JAR choriocarcinoma cells with primer pairs specific for either FR-alpha or FR-beta reveals that while both isoforms 8061055 Human
mov18 ovarian carcinoma We have previously shown that a chimeric IgE antibody against the folic acid receptor (MOv18 IgE) inhibits tumor growth in a SCID mouse model of ovarian carcinoma. 12672069 Mouse
mov18 tumor We have previously shown that a chimeric IgE antibody against the folic acid receptor (MOv18 IgE) inhibits tumor growth in a SCID mouse model of ovarian carcinoma. 12672069 Mouse
mov18 tumor Injection of tumor-bearing mice with PBMC and MOv18 IgE led to infiltration of monocytes into the tumors and prolonged survival of the mice.Incubation of PBMC or purified monocytes and MOv18 IgE with ovarian tumor cells in vitro resulted in tumor cell kil 12672069 Mouse
mov18 tumors Injection of tumor-bearing mice with PBMC and MOv18 IgE led to infiltration of monocytes into the tumors and prolonged survival of the mice.Incubation of PBMC or purified monocytes and MOv18 IgE with ovarian tumor cells in vitro resulted in tumor cell kil 12672069 Mouse
mov 18 carcinoma In contrast, the monoclonal antibodies OC 125, OV-TL 3, OV-TL 16, and MOv 18 can be considered as pan-ovarian carcinoma markers, however without the discriminative capability as seen for OV632. 7678716 Human
fbp human ovarian carcinoma The human ovarian carcinoma cell line, IGROV1, produces two forms of folate binding protein (FBP), the membrane form that is anchored to the cell surface by a glycosylphosphatidylinositol tail and the soluble form that is shed into the tissue culture medi 8428622 Human
folr1 epithelial ovarian cancers In addition, high affinity folate receptor (FOLR1), which maps to 11q13.3-13.5, is expressed at an elevated level on the surface of over 80% of nonmucinous epithelial ovarian cancers. 8094291 Human
folr1 ovarian cancer We studied the involvement of 11q markers in ovarian cancer by looking for tumour-specific loss of heterozygosity (LOH), as well as amplification or rearrangements that might explain the overexpression of FOLR1. 8094291 Human
fbp nasopharyngeal carcinoma Folate-binding protein (FBP), a high-affinity folate receptor, is responsible for cellular accumulation of folate and folate analogs such as methotrexate in human KB (nasopharyngeal carcinoma) cells. 8328990 Human
mov18 carcinoma We studied three carcinoma cell lines, characterized by a different reactivity with the three relevant monoclonal antibodies MOv17, MOv18 and MOv19. 8223571 Human
fbp ovarian carcinoma This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma. 8242637 Human
fbp ovarian carcinoma We have developed a model to investigate the biochemical and biological properties of this folate receptor by transfecting NIH/3T3 cells, which do not endogenously express FBP, with a vector containing the complementary DNA for the gp38 cloned from the ov 8242637 Human
fbp human ovarian carcinoma These results suggest a correlation between human ovarian carcinoma growth and FBP overexpression. 8242637 Human
mov18 ovarian carcinoma These expanded lymphocytes can be targeted to be cytotoxic to ovarian carcinoma cells with a bispecific monoclonal antibody (BsAb) specific for CD3 and for the ovarian carcinoma-associated antigen MOv18. 1386349 Human
folr tumors As a step toward understanding why the adult FOLR gene product is expressed on tumors, we have determined the organization of all the human FOLR-related genes. 1330883 Human
mov18 carcinomas Monoclonal antibody (Mab) MOv18 preferentially reacts with gynecological carcinomas. 1432162 Human
fr-alpha carcinoma Here we report that the FR-alpha gene promoter is repressed in the presence of 17beta-estradiol and derepressed by the antiestrogens tamoxifen and ICI 182780 in a promoter-specific and ER-alpha-dependent manner in carcinoma cell lines including HeLa (cerv 12782587 Human
fr-alpha ovarian carcinoma Here we report that the FR-alpha gene promoter is repressed in the presence of 17beta-estradiol and derepressed by the antiestrogens tamoxifen and ICI 182780 in a promoter-specific and ER-alpha-dependent manner in carcinoma cell lines including HeLa (cerv 12782587 Human
fr-alpha cervical carcinoma Here we report that the FR-alpha gene promoter is repressed in the presence of 17beta-estradiol and derepressed by the antiestrogens tamoxifen and ICI 182780 in a promoter-specific and ER-alpha-dependent manner in carcinoma cell lines including HeLa (cerv 12782587 Human
fr-alpha tumors The results suggest that in ER+ tumors, FR-alpha expression is directly and actively suppressed and predict that a brief treatment with antiestrogens will boost FR-alpha expression by passive derepression, enhancing the efficacy of FR-targeted diagnostic 12782587 Human
fbp nasopharyngeal carcinoma Folate-binding protein (FBP), a high-affinity folate receptor expressed in certain malignant and normal cell lines and tissues, is responsible for cellular transport of folate and structurally related antifolates such as methotrexate in human KB (nasophar 1299378 Human
mov18 ovarian cancer The antibodies tested include 2 antibodies to ovarian cancer, MOv18 and MOv19, one antibody to breast cancer, H23, and one antibody reactive with a range of carcinomas, B72.3. 1988361 Human
mov18 breast cancer The antibodies tested include 2 antibodies to ovarian cancer, MOv18 and MOv19, one antibody to breast cancer, H23, and one antibody reactive with a range of carcinomas, B72.3. 1988361 Human
mov18 carcinomas The antibodies tested include 2 antibodies to ovarian cancer, MOv18 and MOv19, one antibody to breast cancer, H23, and one antibody reactive with a range of carcinomas, B72.3. 1988361 Human
mov 18 ovarian carcinomas The reactivity of MAbs against ovarian carcinoma-associated antigens (OV-TL 3, OC 125, MOv 18, and OV-TL 10) was limited to weak staining reaction in some mesothelial cells but were found to be positive on more than 50% of the ovarian cystadenomas and mor 1992770 Human
mov 18 ovarian carcinoma OC 125, OV-TL 3, and MOv 18 reacted positively with approximately 90% of the ovarian carcinoma samples (n = 80), whereas OV-TL 23 stained 76% of these samples. 2007534 Human
mov 18 carcinomas OC 125, OV-TL 3, and MOv 18 were also reactive with a majority of carcinomas derived from the cervix, endometrium and fallopian tube, while OV-TL 23 reactivity was primarily restricted to ovarian carcinomas. 2007534 Human
mov 18 ovarian carcinomas OC 125, OV-TL 3, and MOv 18 were also reactive with a majority of carcinomas derived from the cervix, endometrium and fallopian tube, while OV-TL 23 reactivity was primarily restricted to ovarian carcinomas. 2007534 Human
mov 18 carcinomas The antibodies MOv 18 and OV-TL 23 were found less reactive with nongynecologic carcinomas. 2007534 Human
mov18 carcinoma Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. 1864729 Human
mov18 human ovarian carcinoma The in vivo behavior of the monoclonal antibody (MAb) MOv18, with a restricted specificity for human ovarian carcinoma was analyzed on normal and tumor-bearing animals. 1864729 Human
fbp ovarian cancer The folate-binding protein locus was not amplified in any of the 16 carcinoma cell lines tested and in only 1 of 10 serous adenocarcinomas, indicating that overexpression of FBP in ovarian cancer cannot, in general, be due to gene amplification. 1717147 Human
fbp serous adenocarcinomas The folate-binding protein locus was not amplified in any of the 16 carcinoma cell lines tested and in only 1 of 10 serous adenocarcinomas, indicating that overexpression of FBP in ovarian cancer cannot, in general, be due to gene amplification. 1717147 Human
fbp carcinoma The folate-binding protein locus was not amplified in any of the 16 carcinoma cell lines tested and in only 1 of 10 serous adenocarcinomas, indicating that overexpression of FBP in ovarian cancer cannot, in general, be due to gene amplification. 1717147 Human
mov18 ovarian carcinoma Monoclonal antibodies MOv18 and MOv19, raised against a membrane preparation of an ovarian carcinoma surgical specimen, react with a surface antigen present on the majority of nonmucinous ovarian malignant tumors tested but not with normal adult tissue (S 1840502 Human
mov18 human ovarian carcinomas We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa glycoprotein homogeneously expressed on the cell surface of 90% of human 1815760 Human
mov18 ovarian carcinoma We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa glycoprotein homogeneously expressed on the cell surface of 90% of human 1815760 Human
mov18 tumor We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa glycoprotein homogeneously expressed on the cell surface of 90% of human 1815760 Human
mov18 ovarian carcinoma Localization studies with radiolabelled MOv18 showed that MOv18 could specifically reach ovarian carcinoma cells growing in the peritoneal cavity of nu/nu mice. 1815760 Mouse
mov18 ovarian carcinoma Bispecific F(ab')2 antibodies made with MOv18 and an antibody reactive with CD3 were able to redirect the cytotoxicity of peripheral blood lymphocytes (PBL) against ovarian carcinoma cells both in vitro and in vivo in an animal model. 1815760 Human
mov18 tumor MOv18 monoclonal antibody in diagnostic applications: capability to recognize the histotype of the original tumor. 2321267 Human
mov18 ovarian carcinoma The immunologic test using the MOv18 MAb, raised against ovarian carcinoma, revealed immunoreactive cells in 83% of the 36 cytologically positive fluids and in one of the 8 negative fluids from ovarian carcinoma patients and in 18% of the 17 fluids from p 2321267 Human
fralpha adenomas The folate receptor (FRalpha) was significantly overexpressed in clinically nonfunctional (NF) adenomas but not in functional adenomas (adrenocorticorticotropic hormone, growth hormone, and prolactin). 12874029 Human
fralpha tumors Analysis of FRalpha expression by Western blotting confirmed that FRalpha protein was specifically overexpressed in NF tumors. 12874029 Human
fralpha adenomas Comparison of protein and specific [(3)H] folic acid binding levels in subtypes of NF adenomas suggested that the immunohistochemically negative adenomas produced more properly folded FRalpha than adenomas that stained positively for anterior pituitary ho 12874029 Human
fralpha adenoma Finally, immunohistochemistry demonstrated that FRalpha was specifically expressed in NF adenoma cells. 12874029 Human
fralpha pituitary adenomas These results demonstrate that overexpression of FRalpha mRNA by NF pituitary adenomas results in production of properly folded FRalpha protein, may mediate vitamin transport, and could potentially facilitate the growth of these tumors. 12874029 Human
fralpha tumors These results demonstrate that overexpression of FRalpha mRNA by NF pituitary adenomas results in production of properly folded FRalpha protein, may mediate vitamin transport, and could potentially facilitate the growth of these tumors. 12874029 Human
fbp myelofibrosis An FBP has been purified from the spleen (FBP-S) of a patient with agnogenic myeloid metaplasia and myelofibrosis. 6947034 Human
fbp agnogenic myeloid metaplasia An FBP has been purified from the spleen (FBP-S) of a patient with agnogenic myeloid metaplasia and myelofibrosis. 6947034 Human
fbp embryonal carcinoma Cell surface carbohydrates of embryonal carcinoma cells: polysaccharidic side chains of F9 antigens and of receptors to two lectins, FBP and PNA. 509522 Human
fbp crohn's disease Median values of FBP for ulcerative colitis were: 13 units/ml (4-74), for Crohn's disease: 14 units/ml (7-73), and healthy volunteers: 14 units/ml (4-51). 2636225 Human
fbp nasopharyngeal epidermoid carcinoma Folate-binding protein (FBP) is responsible for the cellular transport of folate and methotrexate (MTX) in human KB (nasopharyngeal epidermoid carcinoma) cells. 7511899 Human
fbp ovarian tumours We tested the hypothesis of the existence of a defect in the 5, 10-methylenetetrahydrofolate reductase (MTHFR) in ovarian tumours that could cause reduced intracellular regeneration of the 5-methyltetrahydrofolate and induce increased FBP expression. 9099956 Human
fbp ovarian tumours Further studies are needed to assess further the relationship between MTHFR and FBP overexpression, but the demonstration of the alteration of a key metabolic enzyme of the folate cycle in a subset of human ovarian tumours is in accordance with the hypoth 9099956 Human
fbp neoplasias Further studies are needed to assess further the relationship between MTHFR and FBP overexpression, but the demonstration of the alteration of a key metabolic enzyme of the folate cycle in a subset of human ovarian tumours is in accordance with the hypoth 9099956 Human
fbp epithelial tumors Therefore, we have investigated peptides derived from folate binding protein (FBP), which is over-expressed in more than 90% of ovarian cancers and in the majority of other epithelial tumors. 9869522 Human
fbp epithelial tumors Because FBP is over-expressed 20-fold in most adenocarcinomas, these peptides may be used in a widely applicable peptide-based vaccine for epithelial tumors. 9869522 Human
fbp epithelial tumors On a per cell basis, tumor-associated lymphocytes stimulated with the FBP peptides exhibit enhanced cytotoxicity not only against peptide-loaded targets but also against FBP-expressing epithelial tumors of different histologies. 10632363 Human
fbp other tumor Similar results were obtained with peptides mapping CTL epitopes from two other tumor Ag: folate binding protein (FBP) and amino-enhancer of split of Notch (AES). 10767352 Human
folate receptor 1 colonic adenocarcinoma Genes expressed during differentiation included several small-intestine-specific genes involved in nutrient transport/metabolism, e.g., DCT1, hephaestin, folate receptor 1, sucrase-isomaltase, and apolipoproteins CI, CIII, B100, H, and M, indicating that 12644633 Human
folr ovarian tumors There has been interest in the high affinity folate receptor (FOLR) recently because of its high expression in the majority of ovarian tumors. 1330883 Human
fr-alpha aml Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
fr-alpha squamous cell carcinomas of the head and neck FR-alpha alone was expressed in normal epithelial cells and was frequently strikingly elevated in a variety of carcinomas, with the exception of squamous cell carcinomas of the head and neck. 7513252 Human
fr-alpha mucinous tumors In the ovary, benign differentiation of the germinal epithelium into mucinous or serous tumors or malignant transformation into mucinous tumors is associated with down-regulation of FR-alpha, whereas FR-alpha expression is retained in malignant lesions of 10498396 Human
fr-alpha human gastric cancer Our previous study showed that decreased expression of FR-alpha occurs in human gastric cancer cell lines. 15754024 Human
fr-alpha gastric tumors In order to reveal the molecular mechanism of the difference of FR-alpha expression among these cell lines and analyze the relation between the mutations or/and polymorphisms of FR-alpha gene and gastric cancer, we screened the mutations of global FR-alph 15754024 Human
fr-alpha gastric cancer In order to reveal the molecular mechanism of the difference of FR-alpha expression among these cell lines and analyze the relation between the mutations or/and polymorphisms of FR-alpha gene and gastric cancer, we screened the mutations of global FR-alph 15754024 Human
fr-alpha gastric cancer Furthermore, we examined the relationship between two polymorphisms of FR-alpha A1314G and C1816delC and risk for gastric cancer in 296 cases and 354 age and sex-matched controls in northern China. 15754024 Human
fr-alpha gastric cancer These results support the hypothesis that genetic polymorphism in the FR-alpha gene may contribute to susceptibility to carcinogenesis of the gastric cancer in the at-risk Chinese population. 15754024 Human
fr-alpha cell tumor In a murine HeLa cell tumor xenograft model, dexamethasone treatment increased both tumor-associated and serum FR-alpha. 15899836 Mouse
fr-alpha tumors The results support the concept of increasing FR-alpha expression selectively in the receptor-positive tumors by brief treatment with a nontoxic dose of a GR agonist, alone or in combination with a well-tolerated HDAC inhibitor, to increase the efficacy o 15899836 Human
mov-18 human ovarian cancer Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I ( 11299770 Human
mov18 cystadenomas In contrast, MOv18 and MOv19 appeared to have restricted specificities for ovarian carcinomas and cystadenomas. 2434438 Human
mov18 ovarian disease The immunologic test using the MOv18 MAb, raised against ovarian carcinoma, revealed immunoreactive cells in 83% of the 36 cytologically positive fluids and in one of the 8 negative fluids from ovarian carcinoma patients and in 18% of the 17 fluids from p 2321267 Human
mov18 malignant tumors Monoclonal antibodies MOv18 and MOv19, raised against a membrane preparation of an ovarian carcinoma surgical specimen, react with a surface antigen present on the majority of nonmucinous ovarian malignant tumors tested but not with normal adult tissue (S 1840502 Human
mov18 ovarian tumour Multiparameter flow cytometry using two different ovarian tumour markers (MOv18 and BMA180), an anti-cytokeratin monoclonal antibody (MAb) (M9), an anti-vimentin MAb (V9) and a MAb against the panepithelial antigen 17-1A on the fresh ascites cells of the 8054273 Human
mov18 minimal residual disease Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. 7640039 Human
mov18 minimal residual disease Sixteen of 19 enrolled patients with minimal residual disease of ovarian cancer (macroscopic disease < 5 mm or positive blind biopsies and/or positive peritoneal washing), demonstrated by surgical second-look, underwent intraperitoneal radioimmunotherapy 7640039 Human
mov18 ovarian tumor The ovarian tumor markers (OC125, OV-TL 33, OV-TL16, MOv18), all showed an increasing expression level in the sequence order from normal cells to benign and malignant ovarian tumors. 9167042 Human
mov18 subcutaneous tumours The biodistribution of the radiolabelled monoclonal antibodies MOv18, OV185 and OV197 in nude mice with subcutaneous tumours of the human ovarian cancer cell line OVCAR3 was investigated. 10380823 Human
mov18 ovarian tumor Injection of tumor-bearing mice with PBMC and MOv18 IgE led to infiltration of monocytes into the tumors and prolonged survival of the mice.Incubation of PBMC or purified monocytes and MOv18 IgE with ovarian tumor cells in vitro resulted in tumor cell kil 12672069 Mouse
fr alpha ovarian tumor Six ovarian tumor cell lines, expressing different levels of FR alpha (COR > > OVCAR3 > IGROV1 > OVCAR4 > SKOV3 > OVCAR5), were maintained in folate-depleted medium and internalization of 10 nM evaluated as acid-resistant radioactivity at 0 degree and 37 9178098 Human
mov 18 ovarian cystadenomas The reactivity of MAbs against ovarian carcinoma-associated antigens (OV-TL 3, OC 125, MOv 18, and OV-TL 10) was limited to weak staining reaction in some mesothelial cells but were found to be positive on more than 50% of the ovarian cystadenomas and mor 1992770 Human
fr alpha lung metastases A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12/FR alpha that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FR alpha. 10505112 Human
fralpha lung metastases Vaccination with the FRalpha and interleukin-2 cDNA mixture, which was performed after an intravenous injection of FRalpha-transduced cells, enhanced the mean survival time and reduced the number of lung metastases, thus suggesting that such vaccination i 10419053 Human
fralpha other tumors FRalpha is a high affinity folate transporter that is overexpressed by other tumors and could provide a growth advantage to cells that express it. 12874029 Human
fr-alpha acute lymphocytic leukemia (all) Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
fr-alpha chronic lymphocytic leukemia (cll) Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
fr-alpha cml Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
mov18 ovarian carcinoma This surface antigen was purified as a soluble glycoprotein (molecular mass, 36-38 kDa) released from the cell surface of an ovarian carcinoma cell line (IGROV1) by digestion with Bacillus thuringiensis phospholipase C. Immunoblotting demonstrated that th 1840502 Human
mov18 malignant tumors These results indicate that the MOv18 and MOv19 monoclonal antibodies bind to at least one form of folate-binding protein and that this protein, which is evidently overexpressed in certain malignant tumors, may provide a suitable target for immunotherapy 1840502 Human
fbp cml Antiserum raised in rabbits against the FBP obtained from CML cells, and the purified binder labeled with 125I, have been used for an RIA which can measure an immunologically similar protein in human serum. 274499 Human
fbp mds OBJECTIVE: To observe the characteristics of folate binding proteins (FBP) in myelodysplastic syndromes (MDS) and leukemia and to study the clinical significance of reduced folate carrier (RFC) present in MDS and its relationship with multidrug resistance 10374424 Human
fbp renal cell carcinomas The broad distribution of FBP among >90% of ovarian and endometrial carcinomas, as well as 20-50% of breast, lung, colorectal, and renal cell carcinomas, along with pronounced differential overexpression in malignant tissues compared with the extremely li 10632363 Human
fbp methylcholanthrene-induced sarcoma In another model, C57BL/6 mice were given i.v. injections of a syngeneic methylcholanthrene-induced sarcoma transduced with the folate-binding protein (FBP) gene. 7614473 Mouse
mov18 human ovarian carcinomas 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. 15926078 Human
mov18 human ovarian carcinoma The monoclonal antibody (mAb) MOv18 binds the membrane alpha isoform of the folate receptor (FR) which is overexpressed in human ovarian carcinoma cells. 15926078 Human
mov18 tumors These data demonstrate the feasibility of 90Y-labeling of MOv18 without compromising antibody binding ability and the immunoreagent-specific localization in vivo on FR-expressing tumors, suggesting the suitability of 90Y-MOv18 for clinical studies. 15926078 Mouse
fbp cancer Because folate-binding proteins (FBP) are selectively overexpressed on the cancer cell membranes, the folate-bound micelles (FMA) can be guided to the cancer cells in the body, and after the micelles enter the cells, hydrazone bonds are cleaved by the int 16880988 Human
folr1 human tumor Epidemiologic and clinical studies using human tumor specimens are lacking and increasingly needed to understand the role of environmental and genetic influences on FOLR1 expression in tumor etiology and progression. 16453285 Human
folr1 tumor Epidemiologic and clinical studies using human tumor specimens are lacking and increasingly needed to understand the role of environmental and genetic influences on FOLR1 expression in tumor etiology and progression. 16453285 Human
mov18 tumor A cocktail of 125I-c-MOv18 IgG and 131I-c-MOv18 F(ab')2 injected i.v. into an ovarian cancer patient, localized specifically in the tumor. 1432162 Human
mov18 ovarian cancer A cocktail of 125I-c-MOv18 IgG and 131I-c-MOv18 F(ab')2 injected i.v. into an ovarian cancer patient, localized specifically in the tumor. 1432162 Human
mov18 tumor-associated antigen Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. 1840502 Human
mov18 tumor The in vivo behavior of the monoclonal antibody (MAb) MOv18, with a restricted specificity for human ovarian carcinoma was analyzed on normal and tumor-bearing animals. 1864729 Human
mov18 tumor Tumor/non tumor ratios were higher when the time between administration and sacrifice was short and, for 131I-MOv18, with a short interval between labeling and injection. 1864729 Human
mov18 primary tumor Cytological and histopathological characteristics and the expression of tumor-associated antigens OC125 and MOV18 were maintained in the three variants and were comparable to the patient's primary tumor. 1933898 Human
mov18 tumor-associated antigens Cytological and histopathological characteristics and the expression of tumor-associated antigens OC125 and MOV18 were maintained in the three variants and were comparable to the patient's primary tumor. 1933898 Human
mov18 carcinomas Ninety-three percent (26/28) of the effusions from nonmucinous ovarian carcinomas contained MOv18-positive cells, whereas no reactive cells were found in cytologically malignant fluids from patients with ovarian tumors of other oncotypes or with carcinoma 2321267 Human
mov18 ovarian carcinomas Ninety-three percent (26/28) of the effusions from nonmucinous ovarian carcinomas contained MOv18-positive cells, whereas no reactive cells were found in cytologically malignant fluids from patients with ovarian tumors of other oncotypes or with carcinoma 2321267 Human
mov18 ovarian tumors Ninety-three percent (26/28) of the effusions from nonmucinous ovarian carcinomas contained MOv18-positive cells, whereas no reactive cells were found in cytologically malignant fluids from patients with ovarian tumors of other oncotypes or with carcinoma 2321267 Human
fbp tumors Growth analysis revealed that FBP-transfected NIH/3T3 cells like IGROV1 maintained their growth rate after 10 days of culture in medium containing physiological or low folate concentration, and tumors arising after transplanting FBP-tNIH/3T3 cells in nude 8242637 Mouse
fbp adenocarcinomas Because FBP is over-expressed 20-fold in most adenocarcinomas, these peptides may be used in a widely applicable peptide-based vaccine for epithelial tumors. 9869522 Human
fbp leukemia OBJECTIVE: To observe the characteristics of folate binding proteins (FBP) in myelodysplastic syndromes (MDS) and leukemia and to study the clinical significance of reduced folate carrier (RFC) present in MDS and its relationship with multidrug resistance 10374424 Human
fr-alpha malignant transformation In the ovary, benign differentiation of the germinal epithelium into mucinous or serous tumors or malignant transformation into mucinous tumors is associated with down-regulation of FR-alpha, whereas FR-alpha expression is retained in malignant lesions of 10498396 Human
fr-alpha malignant transformation In contrast, malignant transformation of the glandular epithelial cells of the uterine endometrium is associated with de novo expression of FR-alpha. 10498396 Human
fr-alpha malignant transformation In contrast to the uterus, malignant transformation of glandular epithelial cells in the cervix may frequently result in down-regulation of FR-alpha. 10498396 Human
fr-alpha solid tumor FR-alpha surface binding in HeLa cells was shown to be greater than that in a variety of other human solid tumor cell lines. 15585634 Human
mov18 ovarian carcinoma The protective activities of MOv18-IgE and MOv18-IgG1 were compared in a SCID mouse xenograft model of ovarian carcinoma. 10556807 Human
mov18 cancer We investigated the safety and pharmacokinetics of (131)I-labeled chimeric monoclonal antibody MOv18 ((131)I-c-MOv18 IgG) in patients with ovarian cancer and the estimated radiation dose to cancer-free organs and tumor. 10914906 Human
mov18 tumor Also, biodistribution was optimal, and tumor accumulation was superior to that of coinjected (125)I-c-MOv18 labeled according to the conventional IODO-GEN-coated vial method. 11337531 Human
mov18 tumors The ability of 90Y- and 111In-MOv18 to localize FR on tumors in vivo was analyzed in nude mice bearing tumors induced by isogenic cell lines differing only in the presence or absence of the relevant antigen [A431FR (FR-positive) and A431tMock (FR-negative 15926078 Human
fbp tumor Since, folate binding proteins (FBP) and reduced folate carrier proteins (RFC) mediate cellular transport of folate, we compared FBP concentrations in several organs from tumor-bearing transgenic (TBT) mice and tumor-free non-transgenic controls (NTC) of 10390055 Mouse
fbp primary tumors OC cells, isolated from primary tumors, were co-cultured with human peripheral blood mononuclear cells in the presence or absence of various concentrations of BsAbs against PLAP/GCAP, FBP and CA19.9 administered separately or in combination. 10471538 Human
fbp tumor Biodistribution studies with this conjugate in C57BL/6 mice bearing folate receptor (+) murine 24JK-FBP sarcomas resulted in selective tumor uptake (6.0% ID/g tumor), but also high hepatic (38.8% ID/g) and renal (62.8% ID/g) uptake, indicating that attach 12526705 Mouse
fbp sarcomas Biodistribution studies with this conjugate in C57BL/6 mice bearing folate receptor (+) murine 24JK-FBP sarcomas resulted in selective tumor uptake (6.0% ID/g tumor), but also high hepatic (38.8% ID/g) and renal (62.8% ID/g) uptake, indicating that attach 12526705 Mouse
fbp mouse sarcoma METHODS: FR-positive human nasopharyngeal, cervical, ovarian and colorectal cancer cell lines and the transgenic mouse sarcoma (24JK-FBP) cell line were targeted with a novel 99mTc-tricarbonyl folate derivative 2. 16721570 Mouse
fbp colorectal cancer METHODS: FR-positive human nasopharyngeal, cervical, ovarian and colorectal cancer cell lines and the transgenic mouse sarcoma (24JK-FBP) cell line were targeted with a novel 99mTc-tricarbonyl folate derivative 2. 16721570 Human
fbp human tumour In addition, the murine 24JK-FBP cell line proved to be a valuable pre-clinical alternative to human tumour models. 16721570 Mouse
fr-alpha tumor In a murine HeLa cell tumor xenograft model, dexamethasone treatment increased both tumor-associated and serum FR-alpha. 15899836 Mouse
mov18 ovarian tumour We illustrate the new method by analysing human monocyte-mediated cytotoxic and phagocytic cell killing of IGROV1 ovarian tumour cells by the ovarian tumour antigen-specific anti-folate binding protein monoclonal antibody, MOv18 IgE. 17531261 Human
mov18 ovarian cancer An IgE Ab (MOv18 IgE) against an ovarian-tumor-specific Ag (folate binding protein), in combination with human PBMC, introduced into ovarian cancer xenograft-bearing mice, greatly exceeded the analogous IgG1 in promoting survival. 17709497 Human
mov18 ovarian tumor Monocytes mediated MOv18 IgE-dependent ovarian tumor cell killing in vitro by two distinct pathways, cytotoxicity and phagocytosis, acting respectively through the IgE receptors FcepsilonRI and CD23. 17709497 Human
mov18 ovarian tumor We also show that human eosinophils were potent effector cells in MOv18 IgE Ab-dependent ovarian tumor cell cytotoxicity in vitro. 17709497 Human
fbp glioblastoma Anti-EGFR immunoliposomes were then obtained by combining FBP-C225 and folate-liposomes and evaluated for uptake and cytotoxicity in EGFR-overexpressing U87 human glioblastoma cells. 17212981 Human
fbp cancer It has been brought to our attention that one of the folate binding protein (FBP) peptides, which we reported first as antigenic and immunogenic in cancer patients, the FBP 191-199, is "off by one amino acid from the amino acid sequence that is liste 17695510 Human
fbp cancers The large number of mutations in immunogenic FBP-tumor antigens, reported more recently, should be considered during preclinical testing for vaccine and gene therapy in human cancers. 17695510 Human
folr1 uterine cancers The purpose of this study was to examine the expression of FOLR1 in uterine cancers and to identify changes in gene expression that are associated with overexpression of FOLR1. 17400285 Human
folr1 uterine cancer EXPERIMENTAL DESIGN: Fifty-eight frozen uterine cancer specimens were stained for FOLR1 using immunohistochemistry and results were correlated with transcript expression noted on quantitative PCR. 17400285 Human
folr1 cancers USCs overexpressing FOLR1 were compared to cancers with an absence of FOLR1 using binary comparison and template matching of data was used to identify genes that correlate with FOLR1 expression. 17400285 Human
folr1 tumors Using quantitative PCR, both mesothelin (MSLN) and PTGS1 (COX1) were significantly increased in FOLR1 overexpressing tumors (p=0.014 and p=0.006 respectively). 17400285 Human
folr1 tumors OBJECTIVES: Oligonucleotide array and tissue microarray analysis (TMA) by our group has revealed that folate binding protein (FOLR1) is overexpressed in some types of uterine cancer, particularly tumors with serous histology. 17582475 Human
folr1 uterine cancer OBJECTIVES: Oligonucleotide array and tissue microarray analysis (TMA) by our group has revealed that folate binding protein (FOLR1) is overexpressed in some types of uterine cancer, particularly tumors with serous histology. 17582475 Human
folr1 endometrial carcinoma Since FOLR1 overexpression is a frequent event in some types of endometrial carcinoma, we examined the relationship between FOLR1 overexpression and clinical and pathologic features to determine its prognostic relevance. 17582475 Human
folr1 endometrial adenocarcinoma METHODS: A tissue microarray (TMA) comprised of primary tumor specimens from 485 patients diagnosed with endometrial adenocarcinoma was used to identify cases characterized by FOLR1 overexpression. 17582475 Human
folr1 primary tumor METHODS: A tissue microarray (TMA) comprised of primary tumor specimens from 485 patients diagnosed with endometrial adenocarcinoma was used to identify cases characterized by FOLR1 overexpression. 17582475 Human
folr1 tumors RESULTS: Overexpression of FOLR1 was observed in 50/292 (17%) cases and was seen more often in poorly differentiated cancers (22/90 [24%], p=0.051) and tumors with serous histology (16/32 [50%], p<0.001). 17582475 Human
folr1 poorly differentiated cancers RESULTS: Overexpression of FOLR1 was observed in 50/292 (17%) cases and was seen more often in poorly differentiated cancers (22/90 [24%], p=0.051) and tumors with serous histology (16/32 [50%], p<0.001). 17582475 Human
folr1 tumors A shorter progression-free survival was noted in patients with FOLR1 overexpression (log-rank p=0.016) that persisted when the data were limited to patients with stage III/IV disease (log-rank p=0.021) or serous tumors (log-rank p=0.020). 17582475 Human
folr1 endometrial cancer CONCLUSIONS: Our data show that FOLR1 overexpression is not only a biomarker associated with endometrial cancer, but it also appears to be a prognostic factor associated with adverse outcome. 17582475 Human
folr1 endometrial carcinomas These findings suggest that FOLR1 may be an appealing target for biological therapies in some types of endometrial carcinomas. 17582475 Human
fra cancers CONCLUSION: MORAb-003 is an attractive antibody for radioimmunoscintigraphy and possibly radioimmunotherapy of FRA-expressing cancers in addition to its potential direct therapeutic effects. 18355690 Human
fr-alpha cancer In spite of its importance in the diagnosis and treatment of cancer, monoclonal antibodies to FR-alpha suitable for immunohistochemical analysis of formalin-fixed and paraffin-embedded biopsy samples, or that can be used for Western blot analysis, are not 17979543 Human
fr-alpha tumor This preliminary study also supports its use in immunohistochemical studies to determine the role of FR-alpha as a tumor prognostic marker and a possible therapeutic target. 17979543 Human
fr-alpha epithelial cancers The folate receptor (FR) is overexpressed on epithelial cancers (FR-alpha) and on activated, but not resting, macrophages (FR-beta) involved in a variety of inflammatory and autoimmune diseases. 18199624 Human
fr-alpha epithelial cancers FR-alpha expression is frequently amplified in epithelial cancers, whereas FR-beta expression is found in myeloid leukemia and activated macrophages associated with chronic inflammatory diseases. 18318652 Human
fr-alpha myeloid leukemia FR-alpha expression is frequently amplified in epithelial cancers, whereas FR-beta expression is found in myeloid leukemia and activated macrophages associated with chronic inflammatory diseases. 18318652 Human
fr-alpha myeloid leukemia FR-alpha serves as a useful marker for cancer, whereas FR-beta serves as a marker for myeloid leukemia and chronic inflammatory diseases. 18318652 Human
fr-alpha cancer FR-alpha serves as a useful marker for cancer, whereas FR-beta serves as a marker for myeloid leukemia and chronic inflammatory diseases. 18318652 Human
mov18 ovarian tumor We have previously examined a chimeric IgE antibody (MOv18 IgE), against the ovarian tumor-specific antigen, folate binding protein (FBP), and showed that it can direct human PBMC to kill ovarian cancer cells. 17657488 Human
mov18 ovarian cancer We have previously examined a chimeric IgE antibody (MOv18 IgE), against the ovarian tumor-specific antigen, folate binding protein (FBP), and showed that it can direct human PBMC to kill ovarian cancer cells. 17657488 Human
fbp ovarian tumor We have previously examined a chimeric IgE antibody (MOv18 IgE), against the ovarian tumor-specific antigen, folate binding protein (FBP), and showed that it can direct human PBMC to kill ovarian cancer cells. 17657488 Human
fbp ovarian cancer We have previously examined a chimeric IgE antibody (MOv18 IgE), against the ovarian tumor-specific antigen, folate binding protein (FBP), and showed that it can direct human PBMC to kill ovarian cancer cells. 17657488 Human
fbp lymphoma Lymphoma cells evaluated using immunocytochemistry and confocal microscopy showed aberrant multidrug resistance-related protein (MRP) and decreased reduced folate carrier (RFC) and folate binding protein (FBP) expression compared to PIOL cells from anothe 18379939 Human
folr1 non-small-cell lung cancer BACKGROUND: To evaluate the prognostic value of folate receptor alpha (FOLR1) and/or reduced folate carrier (RFC1) expression, which are well-characterized folate transporters, in completely resected non-small-cell lung cancer (NSCLC). 18181001 Human
folr1 nsclc BACKGROUND: To evaluate the prognostic value of folate receptor alpha (FOLR1) and/or reduced folate carrier (RFC1) expression, which are well-characterized folate transporters, in completely resected non-small-cell lung cancer (NSCLC). 18181001 Human
folr1 nsclc METHODS: We quantitatively examined gene expression of FOLR1 and RFC1 in surgical specimens resected from NSCLC patients. 18181001 Human
folr1 adenocarcinoma RESULTS: In adenocarcinoma, the FOLR1 gene expression was downregulated in smokers and male patients (P = 0.006 and P < 0.001, respectively). 18181001 Human
folr1 cancers In addition, FOLR1 expression values in patients with well-differentiated, early p-stage, pT1, pN0, EGFR mutant, and p53 wild-type cancers were significantly higher than those for poorly differentiated, advanced p-stage, pT2-4, pN1-3, EGFR wild-type, and 18181001 Human
folr1 squamous cell carcinoma In squamous cell carcinoma, FOLR1 expression values in patients with pN1-3 was significantly higher than those with pN0 (P = 0.037). 18181001 Human
folr1 lung adenocarcinomas CONCLUSIONS: Higher levels of FOLR1 appear to be associated with better prognoses for patients with lung adenocarcinomas. 18181001 Human
fr-alpha chronic lymphocytic leukemia Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human
fr-alpha acute lymphocytic leukemia Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reactio 8110752 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.